Business
Lifecore Biomedical Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Corporate Update
-- Recorded $128.9 Million in Fiscal 2025 Revenue, Meeting Full-Year Guidance; Maintains Commitment to Mid-Term Outlook -- -- Nine New Programs Signed with New Customers During Fiscal 2025, Reflecting Growth into Modalities Beyond the Company's Traditional Area of Strength in Ophthalmic Therapeutics -- -- Improved Efficiency and Productivity Across the Organization -- Conference Call Today at 4:30pm ET CHASKA, Minn., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Li
About this update from Lifecore Biomedical, Inc.
[{"type":"image","alt":"Lifecore Biomedical, Inc.","displaySize":"","headline":null,"caption":"Lifecore Biomedical, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":127,"url":"https://media.zenfs.com/en/globenewswire.com/2eed086475e8393dea2b97ff03d9e4e2"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/iMQnI4ty5jvtyMU9ZSzRlQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE3ODtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/2eed086475e8393dea2b97ff03d9e4e2","width":300,"height":127}},"lazy":false},{"type":"text","content":"-- Recorded $128.9 Million in Fiscal 2025 Revenue, Meeting Full-Year Guidance; Maintains Commitment to Mid-Term Outlook --","length":123,"tagName":"p"},{"type":"text","content":"-- Nine New Programs Signed with New Customers During Fiscal 2025, Reflecting Growth into Modalities Beyond the Company's Traditional Area of Strength in Ophthalmic Therapeutics --","length":184,"tagName":"p"},{"type":"text","content":"-- Improved Efficiency and Productivity Across the Organization --","length":66,"tagName":"p"},{"type":"text","content":"Conference Call Today at 4:30pm ET","length":34,"tagName":"p"},{"type":"text","content":"CHASKA, Minn., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced its financial results for the fourth quarter and fiscal year 2025.","length":267,"tagName":"p"},{"type":"text","content":"Fourth Quarter and Fiscal Year 2025 Highlights","length":46,"tagName":"p"},{"type":"text","content":"“Driven by our new and highly experienced leadership team, we restructured our organization and implemented numerous efficiencies across the company during fiscal 2025. We right-sized our headcount and reduced expenses as a percentage of revenue, all while increasing our revenue per direct labor employee. Our strengthened organization advanced our growth strategies by executing expansion plans with an existing customer in support of a significant increase in projected demand. We also progressed our late-stage pipeline toward commercialization and added multiple new customers. We are pleased with our business development efforts during fiscal 2025 and are highly encouraged by the progress of our talented new business development team and our growing momentum at fisca...